Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Cash from Operations (2021 - 2025)

Historic Cash from Operations for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to -$2.2 million.

  • Coeptis Therapeutics Holdings' Cash from Operations fell 1371.62% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 2092.42%. This contributed to the annual value of -$6.6 million for FY2024, which is 815.29% up from last year.
  • Latest data reveals that Coeptis Therapeutics Holdings reported Cash from Operations of -$2.2 million as of Q3 2025, which was down 1371.62% from -$2.4 million recorded in Q2 2025.
  • Coeptis Therapeutics Holdings' Cash from Operations' 5-year high stood at -$59847.0 during Q3 2021, with a 5-year trough of -$4.2 million in Q4 2021.
  • For the 5-year period, Coeptis Therapeutics Holdings' Cash from Operations averaged around -$1.5 million, with its median value being -$1.7 million (2023).
  • Data for Coeptis Therapeutics Holdings' Cash from Operations shows a peak YoY increase of 7966.46% (in 2022) and a maximum YoY decrease of 162641.74% (in 2022) over the last 5 years.
  • Coeptis Therapeutics Holdings' Cash from Operations (Quarter) stood at -$4.2 million in 2021, then skyrocketed by 79.66% to -$847352.0 in 2022, then tumbled by 99.89% to -$1.7 million in 2023, then rose by 15.19% to -$1.4 million in 2024, then plummeted by 49.82% to -$2.2 million in 2025.
  • Its Cash from Operations was -$2.2 million in Q3 2025, compared to -$2.4 million in Q2 2025 and -$2.4 million in Q1 2025.